| Property |
Value |
| Category |
Neurotrophic Factor Therapy |
| Target |
Parkinson's Disease |
| Mechanism |
GDNF infusion to protect/repair dopaminergic neurons |
| Status |
Clinical Trials (Phase I/II) |
Glial Cell Line-Derived Neurotrophic Factor (GDNF) is a potent neurotrophic factor that promotes the survival and function of dopaminergic neurons. GDNF therapy represents a promising disease-modifying approach for Parkinson's disease (PD), aiming to protect remaining dopaminergic neurons and potentially restore function to those that are damaged.
GDNF exerts its effects through the following cascade:
- GDNF binds to GFRα1 receptor (GDNF Family Receptor Alpha 1) on the surface of dopaminergic neurons
- Receptor activation triggers RET (Rearranged during Transfection) tyrosine kinase dimerization and autophosphorylation
- Downstream signaling pathways include:
- PI3K/Akt pathway (cell survival)
- MAPK/ERK pathway (neuronal differentiation)
- PLCγ pathway (calcium signaling)
The GDNF-RET complex promotes:
- Dopaminergic neuron survival
- Axonal outgrowth and regeneration
- Restoration of dopamine release
- Protection against oxidative stress
| Trial |
Year |
Approach |
Outcome |
| First human trial |
1995 |
Intraventricular GDNF |
Mixed results, discontinued |
| Phase I trial |
2002 |
Continuous putaminal infusion |
Improved motor scores |
| Phase II trial |
2008 |
Continuous putaminal infusion |
Did not meet primary endpoint |
Modern delivery methods under investigation:
- Convection-enhanced delivery (CED) - Improved distribution
- Gene therapy (AAV-GDNF) - Long-term expression
- Cell therapy - GDNF-secreting cells
- Small molecule GDNF mimetics - Oral delivery
GDNF therapy is being investigated for:
- Early-to-mid stage Parkinson's disease
- Patients with preserved dopaminergic neurons
- Those showing positive response to levodopa
- Patients without cognitive impairment
- Unified Parkinson's Disease Rating Scale (UPDRS) scores
- DaTscan imaging (dopaminergic transporter binding)
- PET imaging (glucose metabolism)
- CSF biomarkers (α-synuclein, neurofilament light chain)
¶ Challenges and Limitations
- Delivery challenges - GDNF does not cross the blood-brain barrier
- Distribution - Ensuring adequate coverage of target brain regions
- Dosing - Optimal therapeutic window
- Safety - Potential off-target effects
- Immunogenicity - Antibody formation against GDNF
- AAV-GDNF gene therapy - Provides continuous GDNF expression
- Novel delivery devices - Improved catheter technology
- Combination approaches - GDNF with other neurotrophic factors
- Biomarker-driven selection - Patient stratification
The study of Gdnf Therapy For Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Gill SS, et al. (2003). Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 9(5):589-595. PMID:12669033
- Slevin JT, et al. (2005). Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg. 102(2):216-222. PMID:15816944
- Lang AE, et al. (2006). Randomized controlled trial of intraputaminal GDNF infusion in Parkinson disease. Arch Neurol. 63(7):987-995. PMID:16862160
- Bartus RT, et al. (2013). Beyond the 6-OHDA model of Parkinson's disease: GDNF and AAV-GDNF. Mol Ther. 21(3):498-505. PMID:23292652
- Hovestadt J, et al. (2020). Gene therapy for Parkinson's disease: AAV-GDNF. Neurobiol Dis. 146:105135. PMID:32980321
- Nurr1 is essential for dopaminergic neuron survival
- Reduced Nurr1 expression in PD patients
- Gene therapy approaches to restore Nurr1
- Small molecule Nurr1 agonists in development
- Tyrosine hydroxylase (TH)
- Dopamine transporter (DAT)
- Vesicular monoamine transporter 2 (VMAT2)
- Retinoic acid receptor beta (RARβ)
- Nurr1 agonists for PD treatment
- Gene therapy with AAV-Nurr1
- Epigenetic modulators to enhance Nurr1 expression
- Combination with other neuroprotective factors